Diana Saraceni

President of the Board, she is Founder and Managing Partner of Panakes Partners SdGR one of the major Med Tech venture investors in Europe. She brings almost 20 years of experience in Venture Capital investments on a large portfolio of successful companies in Italy and Europe.


Andreas Ballis

Diadem Managing Director, Andreas brings experience from delivering corporate business strategy of a publicly traded multinational Pharma as the Senior Vice President for Corporate Business Development (ALAPIS:GA). He brings extensive deal experience in both drugs and medical devices as well as in managing venture investments (King’s College London seed fund). He has prior R&D experience from AstraZeneca and academia (Inserm, Cardiff, Imperial). Former CEO of HRegMed, a successful cell therapy venture. He is an Honorary Fellow at the Imperial College Faculty of Medicine. His Post-doctoral research focused on embryonic stem cell therapy and he holds a Ph.D. in Stem Cell Biology.


Simona Piccirella

Diadem Managing Director, In 2009 she co-founded the company «VisMederi srl» and she was COO until 2016, serving Big Pharma in vaccine immunogenicity evaluation and analytical assay validation. She contributed to the successful authorisation of several vaccines in Europe, USA and Japan. She is co-author of 17 International papers. She is a member of several Italian Business Angels associations that is: IAG (Italian Angels for Growth) and IAB (Italian Angels for Business).


Antonio Boniolo

He served as CEO of DiaSorin SpA, a multinational diagnostics company of 4.1 billion $ market cap. He led the company through growth and brings over thirty years of experience in operational, technical and business aspects in the IVD sector. Currently co-founder and Chairman of Jointherapeutics Srl, a start-up Company focused at developing innovative approaches for the management of osteoarticular pathologies.


Francesco Granata

He is Chairman of Circassia LtD. He is also Chairman of the Nomination Committee. Francesco is Senior Advisor at Warburg Pincus Int. LLC. Prior to this, he was Executive VP at Biogen Idec Inc., and before that, he was Group VP and President responsible for Canada and major European markets at Schering-Plough Corporation. Previously, he served as Regional President for Northern Europe and also Middle East and Africa at Pfizer Inc., and as Managing Director of Pharmacia & Upjohn Inc. in Italy. He is currently a Board member of Italfarmaco SpA, a leading Italian pharmaceutical group that operates in both the pharma and chemical sectors; Prismic Pharmaceuticals Inc., a US based medical food company; Quanta Ltd., a UK company that has developed advanced haemodialysis systems for use in the home and clinic; and a member of the strategic advisory committee at Lupin, a leading Indian global pharmaceutical company.


Prof. Maurizio Memo

Co-Founder and Scientific Advisor, He is Professor at the University of Brescia (Molecular and Translational Medicine Department), recognised for his very impactful contribution to the field of neurodegeneration and the role of DNA damage and repair mechanisms and the molecular basis of amyloid beta pathogenesis and pharmacology, in the context of neurodegeneration.




Bord of Directors - Observers

Prof. Daniela Uberti

Co-Founder and Scientific Advisor: Associate Professor at the University of Brescia (Molecular and Translational Medicine Department) and prior at the Weizmann Institute of Science in Israel. She is the main inventor of Diadem's Technology, pioneered discoveries in the role of p53 in pathogenic mechanisms in neurodegenerative disease and she is very well known in the field. Her impact index is 24,7.


Antonella Fassio

Regulatory Affairs Advisor: She has worked for 23 years in a very successful diagnostic Company: DiaSorin S.p.A.. In her Corporate role of  V.P. Quality Assurance & Regulatory Affairs she worked to guarantee consistency among the Quality Systems of the six manufacturing sites, as an expert of cGMP and 13485:2012. The success of this task was demonstrated by the very positive outcome of several FDA and Notified Bodies inspections. Moreover, worldwide approval of most of the IVD devices produced by DiaSorin S.p.A. showed the capability of organization and successful and continuous meeting of expectations of the Regulatory Bodies, including US and EU. 


Antonio Biscini

Menarini Group Business Development Advisor for IVD market. He worked as Business Development & Licensing Director in Menarini Diagnostics for more than 20 years, bringing significant deal experience in the "In Vitro Diagnostics" market.